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Clinical studies show improved FEV1 in ivacaftor-treated CF patients with the G551D-CFTR mutation
when compared with placebo. To better understand the clinical beneﬁt for those who fall below the
median response, we examined pharmacodynamic and efﬁcacy data from Phase 3 ivacaftor Studies
102/103.
This secondary analysis of patients who received 48 weeks of ivacaftor (n = 109) or placebo (n = 100),
examined the number needed to treat (NNT), frequency and cumulative distribution functions and
subset analyses to evaluate response (sweat chloride, FEV1, weight). Changes in these outcomes
according to FEV1 response were also compared.
The NNT for a reduction in sweat chloride of 20mMol/L was 1.03. To achieve an improvement in
FEV1 of 5%, NNT was 1.73. For both treatment populations, the data were normally distributed
with a shift toward beneﬁt for the ivacaftor group. Numerical differences were seen in sweat chloride
and weight for ivacaftor-treated patients, regardless of whether or not a 5% FEV1 improvement was
achieved (Table).
Ivacaftor was observed to produce an effect on sweat chloride, FEV1, and weight. These analyses
indicate that in % predicted FEV1 responders (5% improvement) and minimal responders (<5% im-
provement) weight gain and change in sweat chloride are similar.
Table 1
Measure Mean change in FEV1 %predicted <5% Mean change in FEV1 %predicted 5%
Study 102 Study 103 Study 102 Study 103
D I (n = 22)
vs.
P (n = 64)
P value D I (n = 10)
vs.
P (n = 18)
P value D I (n = 61)
vs.
P (n = 12)
P value D I (n = 16)
vs. P (n = 6)
P value
%predicted FEV1, % 4.2 <0.0001 1.6 0.5093 6.2 0.0023 9.8 0.0522
[Sweat chloride],
mMol/L
−46.1* <0.0001 −55.8** <0.0001 −49.7† <0.0001 −53.9‡ <0.0001
Body weight, kg 3.3 <0.0001 2.0 0.0582 1.7 0.3313 3.4 0.0094
*Data available for 20 (ivacaftor) and 61 (placebo) patients. **Data available for 9 (ivacaftor) and 17 (placebo) patients.
†Data available for 58 (ivacaftor) and 11 (placebo) patients. ‡Data available for 14 (ivacaftor) and 5 (placebo) patients.
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Objectives: Clinical trials of ivacaftor in CF patients carrying the G551D gene mutation
have shown improvements in FEV1, weight and the risk of pulmonary exacerbation.
However, no reduction in the number of exacerbations requiring intravenous (IV)
antibiotic treatment or hospitalisation was seen. These trials excluded patients with
severe CF (FEV1 <40% predicted), for whom exacerbations and hospitalisations are
more frequent events. We aimed to assess the impact of ivacaftor on exacerbation
frequency and antibiotic days in G551D patients with severe CF (FEV1 <40%).
Methods: 9 CF centres with severe CF patients on compassionate-use ivacaftor in the
UK and Ireland took part. Clinical data were recorded for 1 year prior and a minimum of
3 months post Ivacaftor commencement. The use of antibiotics was deemed a surrogate
for exacerbations. Post-ivacaftor events were normalised to rates per year for analysis.
Results: 16 patients (7 male) received ivacaftor for a median 185 days. Following
Ivacaftor, mean (±sd) rates of antibiotic courses per subject fell from 6.2 (±3.0) to 3.5
(±3.4) per year (p = 0.008). Courses of in-hospital antibiotics similarly decreased from
a median of 3 to 0.73 per year (p = 0.029). Median (IQR) number of IV antibiotic days
reduced from 73 (46–109) to 32 (4−68) days per year, p = 0.0024. Median hospital IV
days fell from 28 (13−76) to 4 (0−33) days per year (p = 0.006).
Conclusions: Ivacaftor signiﬁcantly reduces exacerbation frequency, hospitalisation
rates and in-patient days in CF patients with severe lung function impairment. This
study supports the use of ivacaftor in a patient population which have been previously
excluded from clinical trials.
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Objectives: CFTR modulators are an attractive strategy for mutation-speciﬁc CF
therapy. Results of recent clinical trials pointed to possible differences in organ
speciﬁcity and drug efﬁcacy, raising questions about the choice of the best CFTR
biomarkers. ICM, determining CFTR function in human rectal biopsies, showed
excellent discriminative validity. Aim of this study was to evaluate intra-individual
variability and reliability (within-subject repeatability) of ICM, and to assess
responsiveness to oral ivacaftor treatment.
Methods: ICM was repetitively performed (ECFS ICM SOP) on 3 consecutive time
points (baseline, after 1 & 2 weeks) in each of 10 subjects (mean age 33.6 years,
range 18−53): 4 PI-CF patients, 3 PS-CF patients and 3 healthy controls. A total
of 240 rectal suction biopsies (8/subject per day) was included. Mean, SD and CV
were calculated. Two F508del/G551D-patients started oral treatment with CFTR
modulator ivacaftor directly after ICM at baseline, and responsiveness after 1 and
2 weeks were measured.
Conclusion: For all ICM parameter intra-individual variability between biopsies of
the same day was low. Repetitive ICMs showed repeatable results in >95% of data.
In vivo treatment with ivacaftor normalised rectal CFTR function to levels of non-
CF control.
These ﬁrst data on reliability of ICM demonstrate a low biological intra-subject
variation and a high responsiveness to in vivo Ivacaftor treatment. Clinical trials
evaluating the long-term correlation of ICM to surrogate parameters can facilitate
the transition of ICM to a potential new surrogate parameter in CF drug develop-
ment.
This study was supported by Mukoviszidose e.V., Germany.
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Ivacaftor, a CFTR potentiator, improved CFTR channel activity and lung function in
patients with CF and the G551D-CFTR mutation. Phase 3 studies showed durability of
drug response; however, they provided no information on durability following ivacaftor
withdrawal.
Three randomized, blinded, Phase 2 studies in G551D patients had cross-over designs,
enabling analysis of sweat chloride and clinical markers both during ivacaftor therapy
and following withdrawal. Ivacaftor treatment lasted 14 days in Study 101, and 28 days
in Studies 106/107. All studies measured sweat chloride and FEV1. Additional measures
included lung clearance index (LCI) in 106 and MRI using hyperpolarized gas in 107.
Decreases in sweat chloride and improvements in absolute FEV1 % predicted were
observed during treatment with ivacaftor in all 3 studies (Table). Following ivacaftor
withdrawal (ranging from 7−28 days), sweat chloride and FEV1 returned to near
baseline (Table).
In this analysis with a limited sample, the effects of ivacaftor on CFTR channel activity
and lung function were maintained during treatment and returned to near baseline within
7−28 days following ivacaftor withdrawal, suggesting that continued therapy is required
to sustain improved CFTR activity and lung function.
Study N Mean (SE) change
from baseline
through end of
ivacaftor treatment
P value
within
group
Ivacaftor
treatment
duration
(days)
Mean (SE) change
from baseline
through drug
washout
P value
within
group
Time
since last
ivacaftor
dose (days)
Sweat chloride (mmol/L)
101 3 −54.8 (7.5) * 14 +7.2 (3.5) * 7−28
106 16 −49.0 (3.9) <0.0001 28 −4.0 (2.0) 0.0707 28
107 8 −45.2 (4.2) 0.0078 28 +0.4 (4.0) 0.7422 14
Absolute percent predicted FEV1
101 4 +5.2 (2.0) * 14 +1.9 (2.4) * 7−28
106 18** +7.1 (2.7) 0.0104 28 −1.9 (2.3) 0.7819 28
107 8 +8.8 (2.7) 0.0313 28 −2.1 (2.0) 0.3125 14
